Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03488810
Other study ID # EORTC-1531-ROG
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date March 10, 2020
Est. completion date June 15, 2026

Study information

Verified date August 2020
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of the trial to determine if the combination of apalutamide with 6 months of androgen deprivation therapy by LHRH agonists in patients with intermediate and limited high-risk, localized prostate cancer receiving primary radiation therapy (RT) results in an improvement of disease-free survival (DFS) evaluated by the treating physician, in comparison to the combination of radiation and androgen deprivation therapy without the addition of apalutamide.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 15, 2026
Est. primary completion date June 15, 2026
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Histologically confirmed diagnosis of prostate adenocarcinoma diagnosed by ultrasound guided biopsy of the prostate containing 10-12 cores showing no neuroendocrine component

- Either of: Favorable intermediate risk (according to EAU risk groups): PSA 10-20 ng/mL, -or Gleason score 7 (3 +4) (ISUP Grade 2), or cT2b. Infavorable intermediate risk (according to EAU risk groups): PSA 10-20 ng/mL, -or Gleason score 7 (4+3) (ISUP Grade 3), or cT2b. Limited high risk : PSA > 20 ng/mL or Gleason score >7 (ISUP Grade 4/5)

- M0 by standard imaging work-up

- Scheduled to be treated with primary prostate RT

- WHO Performance Status = 2

- No risk of urinary retention based on the International Prostate Symptom Score (IPSS) : IPSS < 20

- Adequate liver function determined by the following: aspartate aminotransferase (AST), alanine aminotransferase (ALT), < 2.5 x upper limit of normal (ULN). Total bilirubin <1.5 x upper limit of normal (ULN)

- Adequate renal function: creatinine level < 2 x ULN

- Serum albumin = 3.0 g/dL

- Serum potassium = 3.5 mmol/L

- Hemoglobin = 10.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization

- Platelet count = 100,000 x 109/L independent of transfusion and/or growth factors within 3 months prior to randomization

- Be able to swallow whole study drug tablets

Exclusion Criteria:

- cT2c, T3, T4 or pelvic lymph nodes involvement, as assessed by CT scan or MRI (cN1) or pelvic lymph node dissection (pN1)

- Previous pelvic irradiation or radical prostatectomy.

- Bilateral orchiectomy

- Prior systemic (e.g., chemotherapy) or procedural (e.g., prostatectomy, cryotherapy) treatment for prostate cancer

- Prior treatment with 5-alpha reductase inhibitors for benign prostatic hypertrophy not discontinued 4 weeks prior to randomization

- Prior treatment with any LHRH agonist or antagonist, bicalutamide, flutamide or nilutamide, enzalutamide, abiraterone acetate, orteronel, galeterone, ketoconazole, aminoglutethimide, estrogens, megestrol acetate, and progestational agents for prostate cancer

- Prior treatment with radiopharmaceutical agents (e.g., strontium-89) or immunotherapy for prostate cancer

- Other malignancy except adequately treated basal cell carcinoma of the skin or other malignancy from which the patient has been cured for at least 5 years.

- History of Ulcerative Colitis, Crohn's Disease, Ataxia Telangiectasia, systemic lupus erythematosus or Fanconi anemia

- History of seizure or condition that may predispose to seizure (including, but not limited to prior stroke, transient ischemic attack or loss of consciousness = 1 year prior to randomization; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect).

- Medications known to lower the seizure thresholdmust be discontinued or substituted at least 4 weeks prior to study entry

- Certain risk factors for abnormal heart rhythms/QT prolongation: torsade de pointes ventricular arrhythmias (e.g., heart failure, hypokalemia, or a family history of a long QT syndrome), a QT or corrected QT (QTc) interval > 450 ms at baseline

- Uncontrolled hypertension (systolic BP = 140 mmHg or diastolic BP = 90 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment

- Bilateral hip prostheses

- Prior treatment with systemic glucocorticoids = 4 weeks prior to randomization or is expected to require long-term use of corticosteroids during the study

- Use of any investigational agent = 4 weeks prior to randomization

- Current chronic use of opioid analgesics for =3 weeks for oral or = 7 days for non-oral formulations

- Major surgery = 4 weeks prior to randomization

- Known or suspected contraindications or hypersensitivity to apalutamide, bicalutamide or LHRHa agonists or any of the components of the formulations

- Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Radiation Therapy
Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.
Drug:
Apalutamide
240 mg PO daily, started the same day as the first LHRHa injection, for 6 months
Luteinising Hormone Releasing Hormone analog agonist (LHRHa)
2 injections of a three-monthly LHRH agonist depot
Non-steroidal anti-androgen
Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
European Organisation for Research and Treatment of Cancer - EORTC

Outcome

Type Measure Description Time frame Safety issue
Primary Disease-free survival Events for this endpoint include loco-regional recurrence, distant metastases (radiologically or pathologically confirmed), death from any cause, whichever occurs first 7.8 years from First Patient In (FPI)
Secondary Progression-free survival includes first events of biochemical failure by Phoenix criteria in addition to the events listed in the primary endpoint DFS 7.8 years from First Patient In (FPI)
Secondary Distant Metastasis-free survival 7.8 years from First Patient In (FPI)
Secondary Overall survival 7.8 years from First Patient In (FPI)
Secondary Prostate cancer specific survival 7.8 years from First Patient In (FPI)
Secondary Prostate-Specific Antigen (PSA) value Prostate-Specific Antigen (PSA) value will be assessed at the end of the treatment of each patient 5.5 years from First Patient In (FPI)
Secondary Adverse events graded according to the National Cancer Institute Common Occurrence of Adverse Events Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTCAE) version 4.0 7.8 years from First Patient In (FPI)
Secondary Health-related quality of life Health-related quality of life will be evaluated using self-administered EORTC QLQ-C30 questionnaire 7.8 years from First Patient In (FPI)
Secondary Health-related quality of life Health-related quality of life will be evaluated using EORTC QLQ-PR25 instruments 7.8 years from First Patient In (FPI)
Secondary Prostate-Specific Antigen (PSA) nadir Prostate-Specific Antigen (PSA) nadir will be assessed as the lowest value achievement on treatment 5.5 years from First Patient In (FPI)
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A